Thermo Fisher 10-Q Details Q3 GAAP EPS $4.64, $244M Held-for-Sale Loss, $180M More Restructuring
TMO sits 61% above its 52-week low of $435.27 on light trading volume (0.2× avg).
Summary
Thermo Fisher's Q3 10-Q confirms $12.14 billion of revenue and $4.64 GAAP diluted EPS, and newly details a $244 million held-for-sale loss plus about $180 million of additional restructuring charges ahead.
Key Events · Earnings and Guidance · TMO
-
Q3 Revenue $12.14B, GAAP EPS $4.64
Third-quarter revenue of $12,137 million rose 9% from $11,122 million, with GAAP diluted EPS of $4.64 versus $4.27 a year earlier.
-
$244M Held-for-Sale Loss Hits GAAP Margin
A September 4, 2026 agreement to sell a pharma services manufacturing facility produced a $244 million held-for-sale loss in Q3, partly offsetting the $72 million gain on the August 12 microbiology sale.
-
About $180M More Restructuring Ahead
As of October 30, 2026 the company identified restructuring actions, primarily in Laboratory Products and Biopharma Services, expected to cost roughly $180 million, mostly in 2026.
-
Nine-Month Free Cash Flow $4.62B
Operating cash flow of $5,867 million less $1,263 million of capital purchases and $14 million of proceeds gives free cash flow of $4,618 million, up from $3,319 million a year earlier.
Analysis · TMO · Industrial Applications And Services
The headline numbers were already public on October 21, but the full 10-Q fills in what the press release did not: GAAP diluted EPS of $4.64 on $12,137 million of revenue, a $244 million held-for-sale loss on the pharma services facility sale that dragged GAAP operating margin, and roughly $180 million of additional restructuring charges still to come, mostly in Laboratory Products and Biopharma Services. Cash generation remains the strong part of the story, with $5,867 million of operating cash flow and $4,618 million of free cash flow through nine months. The tax line is noisy rather than informative: a $161 million deferred benefit from domestication transactions was largely offset by $171 million of tax on the microbiology sale gain.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TMO was trading at $699.82 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $258.8B. The 52-week trading range was $435.27 to $711.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.